GGrantIndex
← Leaderboards

Susan E Dorman

Johns Hopkins University

$18,489,626
Attributed
$39,688,051
Total exposure
12
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.2M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$36,400,393 · 10
FDA$3,287,658 · 2

By mechanism

U01$19,752,680 · 1
R01$17,601,483 · 6
K24$790,188 · 1
K23$657,450 · 1
R21$489,492 · 1
R34$240,878 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Tuberculosis

Research focus

TuberculosisMycobacterium TuberculosisPharmaceutical PreparationsTuberculosis TreatmentDiagnosticFutureDiagnosisProgramsLaboratoriesFundingCommunicable DiseasesUnited States National Institutes Of HealthCostDetectionSputumDiagnostic TestsBaseDiagnostics ResearchPredispositionPulmonary TuberculosisSpecimenEvaluationCharacteristicsDesign

Grant awards (48)

FEND-TB$2,593,818
R01 · FY2025 · AI
FEND-TB$298,587
R01 · FY2025 · AI
Novel strategies for treatment of Mycobacterium abscessus pulmonary disease$240,878
R34 · FY2025 · AI · contact PI
FEND-TB$196,955
R01 · FY2025 · AI
FEND for TB$3,689,474
U01 · FY2024 · AI
FEND for TB$3,943,297
U01 · FY2023 · AI
FEND for TB$4,167,230
U01 · FY2022 · AI
FEND for TB$3,954,651
U01 · FY2021 · AI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$100,000
R01 · FY2021 · FD
FEND for TB$3,998,028
U01 · FY2020 · AI
Novel Biomarkers to Shorten TB Treatment$659,830
R01 · FY2020 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$556,523
R01 · FY2020 · AI · contact PI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,180,603
R01 · FY2019 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$709,366
R01 · FY2019 · AI
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$157,476
K24 · FY2019 · AI · contact PI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,325,755
R01 · FY2018 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$725,266
R01 · FY2018 · AI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2018 · FD
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$157,476
K24 · FY2018 · AI · contact PI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,424,115
R01 · FY2017 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$728,068
R01 · FY2017 · AI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2017 · FD
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$83,934
K24 · FY2017 · AI · contact PI
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$73,542
K24 · FY2017 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$672,409
R01 · FY2016 · AI
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$157,476
K24 · FY2016 · AI · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2015 · FD
Lipidated Mycobacterium tuberculosis biomarkers in clinical specimens$226,328
R21 · FY2015 · AI · contact PI
Multidisciplinary Clinical Research and Mentoring in Tuberculosis Diagnostics$160,284
K24 · FY2015 · AI · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2014 · FD
Lipidated Mycobacterium tuberculosis biomarkers in clinical specimens$1
R21 · FY2014 · AI · contact PI
Lipidated Mycobacterium tuberculosis biomarkers in clinical specimens$263,163
R21 · FY2013 · AI · contact PI
Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa$682,980
R01 · FY2012 · AI · contact PI
Phase II Study of Daily Rifapentine for Pulmonary Tuberculosis (IND 62,611; 1/2/0$387,658
R01 · FY2012 · FD · contact PI
Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa$660,654
R01 · FY2011 · AI · contact PI
Phase II Study of Daily Rifapentine for Pulmonary Tuberculosis (IND 62,611; 1/2/0$400,000
R01 · FY2011 · FD · contact PI
Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa$608,927
R01 · FY2010 · AI · contact PI
Phase II Study of Daily Rifapentine for Pulmonary Tuberculosis (IND 62,611; 1/2/0$400,000
R01 · FY2010 · FD · contact PI
Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa$620,472
R01 · FY2009 · AI · contact PI
Phase II Study of Daily Rifapentine for Pulmonary Tuberculosis (IND 62,611; 1/2/0$400,000
R01 · FY2009 · FD · contact PI
Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa$669,497
R01 · FY2008 · AI · contact PI
Rapid Detection of Mycobacterium tuberculosis$131,490
K23 · FY2007 · AI · contact PI
Rapid Detection of Mycobacterium tuberculosis$131,490
K23 · FY2006 · AI · contact PI
Rapid Detection of Mycobacterium tuberculosis$131,490
K23 · FY2005 · AI
Rapid Detection of Mycobacterium tuberculosis$131,490
K23 · FY2004 · AI
Mycobacterium tuberculosis cell wall virulence factors$78,575
R03 · FY2004 · AI
Rapid Detection of Mycobacterium tuberculosis$131,490
K23 · FY2003 · AI
Mycobacterium tuberculosis cell wall virulence factors$77,305
R03 · FY2003 · AI